This statement provides recommendations for use of Zostavax™ in Canadian adults.
As new information regarding Zostavax™ and/or the burden of illness becomes available, the recommendations will be reviewed. Issues including cost-effectiveness, acceptability of vaccine programs, and feasibility will be addressed by other provincial or federal groups.
January, 2010